ATNF (180 Life Sciences Corp.) Short-Term Debt to Equity Ratio

This price chart illustrates the price action of ETHZilla Corporation (ATNF), whose previous revenues relied on developing antibodies for fibrosis and pain therapy. ETHZilla Corporation (ATNF) has now pivoted to accumulating Ethereum and tokenization in partnership with Electric Capital, with the metric standing at 0.07. As a result of a radical restructuring, the business has completely shifted its profile, abandoning biotechnology in favor of expansion into the digital asset sector.

This indicator assesses the company's reliance on short-term borrowing relative to its equity, allowing investors to identify the risk of a cash gap during a sharp increase in liabilities. By analyzing the current trend of short-term liabilities to equity, one can evaluate the viability of ETHZilla Corporation (ATNF) in the absence of stable financing and amidst high risks of clinical program failures, which is critical for preventing a cessation of operations.